Literature DB >> 24302624

A modified ELISA accurately measures secretion of high molecular weight hyaluronan (HA) by Graves' disease orbital cells.

Christine C Krieger1, Marvin C Gershengorn.   

Abstract

Excess production of hyaluronan (hyaluronic acid [HA]) in the retro-orbital space is a major component of Graves' ophthalmopathy, and regulation of HA production by orbital cells is a major research area. In most previous studies, HA was measured by ELISAs that used HA-binding proteins for detection and rooster comb HA as standards. We show that the binding efficiency of HA-binding protein in the ELISA is a function of HA polymer size. Using gel electrophoresis, we show that HA secreted from orbital cells is primarily comprised of polymers more than 500 000. We modified a commercially available ELISA by using 1 million molecular weight HA as standard to accurately measure HA of this size. We demonstrated that IL-1β-stimulated HA secretion is at least 2-fold greater than previously reported, and activation of the TSH receptor by an activating antibody M22 from a patient with Graves' disease led to more than 3-fold increase in HA production in both fibroblasts/preadipocytes and adipocytes. These effects were not consistently detected with the commercial ELISA using rooster comb HA as standard and suggest that fibroblasts/preadipocytes may play a more prominent role in HA remodeling in Graves' ophthalmopathy than previously appreciated.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24302624      PMCID: PMC3891933          DOI: 10.1210/en.2013-1890

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  37 in total

1.  Adipose thyrotrophin receptor expression is elevated in Graves' and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo.

Authors:  K J Starkey; A Janezic; G Jones; N Jordan; G Baker; M Ludgate
Journal:  J Mol Endocrinol       Date:  2003-06       Impact factor: 5.098

2.  Studies on hyaluronic acid. I. The preparation and properties of rooster comb hyaluronic acid.

Authors:  D A Swann
Journal:  Biochim Biophys Acta       Date:  1968-02-01

3.  Expression of hyaluronan synthase messenger ribonucleic acids and their induction by interleukin-1beta in human orbital fibroblasts: potential insight into the molecular pathogenesis of thyroid-associated ophthalmopathy.

Authors:  L A Kaback; T J Smith
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

4.  TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients.

Authors:  I M M J Wakelkamp; O Bakker; L Baldeschi; W M Wiersinga; M F Prummel
Journal:  Clin Endocrinol (Oxf)       Date:  2003-03       Impact factor: 3.478

5.  Myofibroblastic differentiation leads to hyaluronan accumulation through reduced hyaluronan turnover.

Authors:  Robert H Jenkins; Gareth J Thomas; John D Williams; Robert Steadman
Journal:  J Biol Chem       Date:  2004-07-22       Impact factor: 5.157

6.  Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves' ophthalmopathy and pretibial dermopathy.

Authors:  A E Heufelder; C M Dutton; G Sarkar; K A Donovan; R S Bahn
Journal:  Thyroid       Date:  1993       Impact factor: 6.568

7.  Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy.

Authors:  Seema Kumar; Michael J Coenen; Philipp E Scherer; Rebecca S Bahn
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

8.  Immunohistochemical and ultrastructural studies on the exenterated orbital tissues of a patient with Graves' disease.

Authors:  T J Hufnagel; W F Hickey; W H Cobbs; F A Jakobiec; T Iwamoto; R C Eagle
Journal:  Ophthalmology       Date:  1984-11       Impact factor: 12.079

9.  Modulation of TGFbeta1-dependent myofibroblast differentiation by hyaluronan.

Authors:  Jason Webber; Robert H Jenkins; Soma Meran; Aled Phillips; Robert Steadman
Journal:  Am J Pathol       Date:  2009-06-18       Impact factor: 4.307

10.  Hormonal regulation of hyaluronate synthesis in cultured human fibroblasts: evidence for differences between retroocular and dermal fibroblasts.

Authors:  T J Smith; R S Bahn; C A Gorman
Journal:  J Clin Endocrinol Metab       Date:  1989-11       Impact factor: 5.958

View more
  6 in total

1.  TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis.

Authors:  Christine C Krieger; Susanne Neumann; Bernice Marcus-Samuels; Marvin C Gershengorn
Journal:  Thyroid       Date:  2017-03-27       Impact factor: 6.568

2.  Inhibiting thyrotropin/insulin-like growth factor 1 receptor crosstalk to treat Graves' ophthalmopathy: studies in orbital fibroblasts in vitro.

Authors:  Robert F Place; Christine C Krieger; Susanne Neumann; Marvin C Gershengorn
Journal:  Br J Pharmacol       Date:  2017-01-27       Impact factor: 8.739

3.  Inhibition of TSH/IGF-1 Receptor Crosstalk by Teprotumumab as a Treatment Modality of Thyroid Eye Disease.

Authors:  Christine C Krieger; Xiangliang Sui; George J Kahaly; Susanne Neumann; Marvin C Gershengorn
Journal:  J Clin Endocrinol Metab       Date:  2022-03-24       Impact factor: 5.958

4.  Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins.

Authors:  Christine C Krieger; Susanne Neumann; Robert F Place; Bernice Marcus-Samuels; Marvin C Gershengorn
Journal:  J Clin Endocrinol Metab       Date:  2014-12-08       Impact factor: 5.958

Review 5.  Molecular Insights Into the Relationship Between Autoimmune Thyroid Diseases and Breast Cancer: A Critical Perspective on Autoimmunity and ER Stress.

Authors:  Safikur Rahman; Ayyagari Archana; Arif Tasleem Jan; Durgashree Dutta; Abhishek Shankar; Jihoe Kim; Rinki Minakshi
Journal:  Front Immunol       Date:  2019-03-01       Impact factor: 7.561

6.  Proximity ligation assay to study TSH receptor homodimerization and crosstalk with IGF-1 receptors in human thyroid cells.

Authors:  Christine C Krieger; Alisa Boutin; Susanne Neumann; Marvin C Gershengorn
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-29       Impact factor: 6.055

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.